Bezuclastinib Achieves Positive PEAK Phase 3 Results in Advanced GIST: A Potential New Standard for KIT Exon 17/18 Mutant Disease

Gastrointestinal stromal tumors (GISTs) are driven primarily by oncogenic KIT mutations, and breakthroughs such as imatinib, sunitinib, and ripretinib have transformed the disease’s management. Yet resistance emerges almost…